Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019
Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020
Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015
Age, risk and outcomes in idiopathic pulmonary arterial hypertension Source: Eur Respir J, 51 (5) 1800629; 10.1183/13993003.00629-2018 Year: 2018
Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018 Year: 2019
Analysis of mortality risk factors in a population with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010
Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020
Optimising the management of pulmonary arterial hypertension patients: emergency treatments Source: Eur Respir Rev 2010 19: 204-211 Year: 2010
Comparison of prevalence of diabetes mellitus in patients with idiopathic pulmonary arterial hypertension and distal chronic thromboembolic pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013
Pulmonary rehabilitation in patients with pulmonary arterial hypertension Source: ERS Course 2017 Year: 2017
Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008
Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016
COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey Source: ERJ Open Res, 6 (4) 00520-2020; 10.1183/23120541.00520-2020 Year: 2020
Good outcomes following elective lower limb orthopaedic surgery in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018
Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010
Critical care admissions in patients with pulmonary arterial hypertension. Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018
Chronic thrombo-embolic pulmonary hypertension: Long-term outcomes in operated and non-operated patients Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016
The French registry of pulmonary arterial hypertension in children: characteristics at diagnosis Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011
Optimising pharmacotherapy in patients with pulmonary arterial hypertension and comorbidities, including lung diseases and heart failure: benefits without harm? Source: International Congress 2018 – Integrated care for patients with pulmonary vascular disease, lung diseases and heart failure Year: 2018